Edgewise Therapeutics (EWTX) Total Non-Current Liabilities (2021 - 2022)
Edgewise Therapeutics' (EWTX) quarterly Total Non-Current Liabilities came in at $10.9 million in Q2 2022, down 11.06% quarter-over-quarter from $12.2 million in Q1 2022.
Edgewise Therapeutics (EWTX) Total Non-Current Liabilities (2021 - 2022) Analysis & Trends
Edgewise Therapeutics has disclosed Total Non-Current Liabilities across 2 years of filings, most recently posting $10.9 million for Q2 2022.
- Total Non-Current Liabilities for Q2 2022 came in at $10.9 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2022 was $10.9 million (changed N/A YoY), and the FY2021 annual result was $10.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities came in at $10.9 million for Q2 2022 at Edgewise Therapeutics, down from $12.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $12.2 million in Q1 2022 to a low of $8.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Edgewise Therapeutics | 3.52 Bn | 3.52 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 10.85 Mn |
| Mar 31, 2022 | 12.20 Mn |
| Dec 31, 2021 | 10.52 Mn |
| Sep 30, 2021 | 8.75 Mn |